Drug Trial Radar · NCT06066827
Hair Regeneration in Androgenetic Alopecia
Last checked: Nov 19, 2026Latest source record: Oct 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Actual
Start
Aug 14, 2023
Primary completion
Nov 30, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- Dr. dr. Lili Legiawati, SpKK(K)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Education, Culture, Research, and Technology, Republic of Indonesia; PT. Kimia Farma (Persero) Tbk
- First posted
- Oct 4, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial study aims to compare the effectiveness and safety of secretome from ADSCs with minoxidil in AGA cases, to provide future reference or standard in the application of cell-based therapy and its derivatives in AGA cases. The subject of this study is androgenetic alopecia population. The main questions it aims to answer are: * Is the secretome of ADSC's effective compared to minoxidil? * Is the secretome of ADSC's safe compared to minoxidil? * Is the combination of the secretome of ADSC's and minoxidil better in safety and effectiveness compared to secretome or minoxidil alone?
Conditions
- Androgenetic Alopecia
Interventions
Minoxidil TopicalDrug
20 subjects received minoxidil only for the treatment of AGA
Secretome from adipose-derived stem cellsOther
20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
Combination of minoxidil and secretome from adipose-derived stem cellsCombination product
20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement of alopecia in physical examinationTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
- Macroscopic hair growth documentedTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
- Microscopic hair growth evaluated by TrichoscopyTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
- Microscopic hair growth evaluated by TrichoscanTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
RSUP Nasional Cipto Mangunkusumo
Jakarta Pusat, DKI Jakarta, Indonesia
Universitas Indonesia
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.